UnknownNot Applicable

Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage

50 participantsStarted 2017-01

Plain-language summary

Recently, the occurrence and potential impact of pituitary dysfunction after aSAH has gained increasing interest. Several studies have demonstrated pituitary dysfunction after SAH suggesting that pituitary dysfunction may be a contributing factor for residual symptoms after SAH. This is an observational multicentric study aimed to test the prevalence of thyroid abnormalities, other neuroendocrinological dysfunction and their influence on outcome of patients affected by aSAH.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with acute aneurysmal SAH aged between 18 and 70 years of age who could be subjected to endocrine evaluation within 10 days of ictus and at follow-up. Exclusion Criteria: * be major depression, psychiatric premorbidity, pituitary adenoma or perisellar lesion,preexisting hypopituitarism of any degree, previous hormonal substitution, patients in moribund state, pregnancy, glucocorticoid medication on admission to hospital or during treatment, prior pituitary insufficiency, and unsalvageable aSAH.

What they're measuring

Incidence of thyroid disfunction

Timeframe: At 2 weeks after aSAH

Incidence of thyroid disfunction

Timeframe: 3 months after aSAH

Incidence of thyroid disfunction

Timeframe: 6 months after aSAH

Incidence of thyroid disfunction

Timeframe: 12 months after aSAH

Trial details

NCT IDNCT02915380

SponsorDr. Rita Bertuetti

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-01

Contact for this trial

Chiara Robba, MD

kiarobba@gmail.com

View on ClinicalTrials.gov More Thyroid Disfunction trials